A/Prof. Daniel Scott co-heads the Drug Discovery Innovation laboratory at The Florey Institute and is Managing Director and Chair of LASEREDD Therapeutics, a Melbourne-based biotechnology company. Daniel has over 20 years’ experience researching all aspects of GPCR function, with a focus on developing new methods to further GPCR molecular pharmacology, structural biology and drug discovery. In 2008 Daniel was awarded a postdoctoral fellowship to work in the renowned antibody and protein engineering laboratory of Prof. Andreas Plückthun in Zurich, Switzerland. While in Zurich he invented a novel method, called CHESS, which enabled the rapid engineering of stabilized membrane proteins through directed evolution for X-ray crystallography. The CHESS technology was spun out into a company, called G7 therapeutics, co-founded by Daniel in 2013. In 2016 G7T was acquired by Sosei Heptares, who continue to use CHESS for drug discovery. In November 2011, Daniel took up a group leader position at The Florey, with the team focused on using protein engineering, protein design and directed evolution to further our molecular understanding of GPCR function and for drug discovery. Daniel has published over 61 research articles and is an inventor on four patents. The group recently licensed a suite of intellectual property comprising the LASEREDD® platform, to LASEREDD Therapeutics, which is led by Daniel and is focused on enabling next-generation discovery of therapeutics targeting GPCRs.